r. mousazadeh

Treatment of breast cancer has many problems due to the systemic effects of chemotherapy. The use of certain molecules with cell killing effects, such as aflatoxin B1, can have fatal effects on breast cancer cells. In this study, we investigated the inhibitory effect of topical aflatoxin B1 use on breast cancer. Class 4T1 cancer cells were inoculated subcutaneously in female mice. Doses of 50 and 500 μg / ml of aflatoxin B1 were then injected around the tumors in comparison with doxorubicin. The ratio of tumor size to animal weight in different groups was evaluated along with histopathology by immunofluorescence on Ki-67 and VEGF indices. Aflatoxin B1 significantly reduces tumor volume, necrosis and suppresses angiogenesis in the tumor. However, liver metastasis occurred in all groups. Aflatoxin B1 in topical injections of 50 and 500 μg / ml around the tumor has anti-cancer effects on the breast. But it can not prevent metastasis.Aflatoxin-induced hepatotoxicity was also observed.

Contrast induced nephropathy (CIN) is one the complications resulting from coronary catheterization and is regarded as one of the reasons of acute kidney failure. Therefore، this study aimed to investigate the effect of ascorbic acid in the prevention of CIN in Yazd in 2012.

This study involves a double blind clinical trial in which 90 Diabetic patients with coronary catheterization have attended. The patients were divided randomly into two groups: control group and treatment group. Demographic and clinical data were collected by a questionnaire. Treatment group received vitamin C (2 grams) 2 hours before the intervention and the control groups were given 2 grams of the Placebo. The GFR (Glomerular filtration rate)، BUN (Blood Urea Nitrogen)، and Cr (Creatinin) were measured and compared after 2-3 days.

The CIN in treatment group was about 3 patients (7. 7%) and was 7 (16. 7%) in the control group. Thus، no significant difference was observed; though، there was a significant difference between Cr and GFR before and after the treatment in vitamin C group (PV= 0. 006، PV=0. 001)، but these differences were not significant in the placebo group. (PV=0. 661، PV=0. 747). Moreover، considering the participants’ age، sex and their primary function of kidney، a significant difference had not appeared due to the incidence of CIN between the two groups.

Our study did not show Ascorbic Acid effects in prevention of CIN in Diabetic patients.